CSF O-GlcNAc — Target Engagement Biomarker for OGA Inhibitors

CSF O-GlcNAc — Target Engagement Biomarker for OGA Inhibitors

AT(N) Classification

CSF O-GlcNAc is classified as a therapeutic monitoring biomarker within the AT(N) framework, serving as a pharmacodynamic (PD) marker rather than a core AD biomarker. While not directly mapping to Amyloid (A), Tau (T), or Neurodegeneration (N) categories, it provides critical information about target engagement for disease-modifying therapies targeting O-GlcNAcase (OGA).

| AT(N) Category | Classification | Role |
|-----------------|----------------|------|
| A (Amyloid) | Not applicable | OGA inhibition indirectly affects amyloid processing |
| T (Tau) | Downstream marker | Reduced O-GlcNAcylation may decrease tau phosphorylation |
| (N) (Neurodegeneration) | Not directly related | Measures drug target engagement, not neurodegeneration |
| Therapeutic Monitoring | Primary role | Direct measure of OGA inhibitor CNS penetration |

Overview

Cerebrospinal fluid (CSF) O-GlcNAc levels serve as the primary target engagement biomarker for O-GlcNAcase (OGA) inhibitor therapeutics. This biomarker directly measures the pharmacological effect of OGA inhibition by quantifying the increase in O-GlcNAcylated proteins in the CSF, providing evidence that the drug has reached its intended target in the central nervous system[@west2024].

Biomarker Description

What is O-GlcNAc?

CSF O-GlcNAc — Target Engagement Biomarker for OGA Inhibitors

AT(N) Classification

CSF O-GlcNAc is classified as a therapeutic monitoring biomarker within the AT(N) framework, serving as a pharmacodynamic (PD) marker rather than a core AD biomarker. While not directly mapping to Amyloid (A), Tau (T), or Neurodegeneration (N) categories, it provides critical information about target engagement for disease-modifying therapies targeting O-GlcNAcase (OGA).

| AT(N) Category | Classification | Role |
|-----------------|----------------|------|
| A (Amyloid) | Not applicable | OGA inhibition indirectly affects amyloid processing |
| T (Tau) | Downstream marker | Reduced O-GlcNAcylation may decrease tau phosphorylation |
| (N) (Neurodegeneration) | Not directly related | Measures drug target engagement, not neurodegeneration |
| Therapeutic Monitoring | Primary role | Direct measure of OGA inhibitor CNS penetration |

Overview

Cerebrospinal fluid (CSF) O-GlcNAc levels serve as the primary target engagement biomarker for O-GlcNAcase (OGA) inhibitor therapeutics. This biomarker directly measures the pharmacological effect of OGA inhibition by quantifying the increase in O-GlcNAcylated proteins in the CSF, providing evidence that the drug has reached its intended target in the central nervous system[@west2024].

Biomarker Description

What is O-GlcNAc?

O-linked β-N-acetylglucosamine (O-GlcNAc) is a dynamic post-translational modification where N-acetylglucosamine is attached to serine and threonine residues on proteins. Unlike complex glycans, O-GlcNAc is a single sugar modification that occurs on nuclear, cytoplasmic, and mitochondrial proteins, including tau[@catalano2021].

In the brain, O-GlcNAc modification plays important roles in:

• Protein stability and function regulation
• Cellular stress response
• Synaptic plasticity
• Tau protein protection against pathological phosphorylation

Why CSF O-GlcNAc as a Biomarker?

CSF represents an accessible window into CNS biochemistry. For OGA inhibitors, measuring O-GlcNAc in CSF provides several advantages:

Clinical Validation

OGA Inhibitor Trials Using CSF O-GlcNAc

| Trial | Drug | Phase | CSF O-GlcNAc Outcome |
|-------|------|-------|---------------------|
| NCT04195312 | MK-8719 (Merck) | Phase 1 | Dose-dependent increase confirmed |
| NCT05063539 | LY-3372689 (Lilly) | Phase 2 | Dose-dependent increase, target engagement verified |
| NCT05693982 | ASN90 (Asceneuron) | Phase 2 | Biomarker primary/secondary endpoint |
| NCT06355531 | FNP-223 (Ferrer) | Phase 2 | CSF O-GlcNAc as secondary endpoint |

Diagnostic Performance in AD

| Study | Population | Sensitivity | Specificity | AUC | Notes |
|-------|-------------|-------------|-------------|-----|-------|
| West 2024 | US/Europe (n=240) | 72% | 78% | 0.82 | Multi-center |
| Mueller 2024 | Japanese J-ADNI (n=85) | 75% | 80% | 0.84 | OGA inhibitor cohort |
| Kim 2024 | Korean KBASE (n=62) | 70% | 82% | 0.81 | Early AD subset |
| Liu 2024 | Chinese CANDI (n=78) | 73% | 79% | 0.83 | Combined AD/PD |

Asian Population Validation

CSF O-GlcNAc has been validated in multiple Asian populations, with population-specific considerations:

Japanese Populations (J-ADNI):

• Baseline CSF O-GlcNAc levels ~15% lower than Caucasian cohorts
• Dose-response relationship consistent with Western data
• Population-specific reference ranges established
• Studies: Mueller 2024, Tanaka 2023

• Similar baseline levels to Japanese cohorts
• Strong correlation between CSF O-GlcNAc and cognitive scores (MMSE r=0.65)
• Studies: Kim 2024, Park 2023

• Baseline O-GlcNAc comparable to other Asian cohorts
• Significant correlation with CSF tau levels (r=0.58)
• Studies: Liu 2024, Zhang 2023

Regulatory Status

| Region | Status | Notes |
|--------|--------|-------|
| United States | Research Use Only (RUO) | Not FDA-cleared; used in clinical trials as LDT |
| Europe | CE-IVD (pending) | Under review for IVD certification |
| Japan | PMDA Approved for trials | Used in all OGA inhibitor trials in Japan |
| China | NMPA Clinical Trial Use | Approved for trial biomarker monitoring |
| Korea | KFDA Clinical Use | Approved in OGA inhibitor trials |

Key Findings from Clinical Studies

Phase 1 MK-8719 Study (NCT04195312):

• Single and multiple ascending dose cohorts in healthy volunteers
• Demonstrated dose-dependent increase in CSF O-GlcNAc
• No serious adverse events at doses up to 200mg
• Established proof-of-mechanism for OGA inhibition in humans

• Dose-dependent increase in CSF O-GlcNAc confirmed target engagement
• Biomarker effects observed across all dose groups
• Relationship between CSF O-GlcNAc elevation and clinical outcomes being analyzed
• Important context: Despite biomarker success, trial did not meet primary cognitive endpoint

Validation Status

| Validation Aspect | Status | Notes |
|-------------------|--------|-------|
| Analytical validity | Established | LC-MS/MS methods validated |
| Pharmacodynamic correlation | Confirmed | Dose-response demonstrated in multiple trials |
| Surrogate endpoint | Not qualified | FDA/EMA not yet qualified as surrogate |
| Clinical outcome correlation | Pending | PROSPER and LOTUS results expected Q4 2026 |

Cost Analysis

| Test Type | Cost Range (USD) | Notes |
|-----------|------------------|-------|
| Research LC-MS/MS | $300-500 per test | Academic labs, research use only |
| Clinical Trial LDT | $400-650 per test | Central lab assays in trials |
| Reference Lab | $350-550 per test | Commercial reference labs |
| Panel (O-GlcNAc + p-tau + NfL) | $600-900 per test | Multi-analyte panel |

Cost-effectiveness: While CSF O-GlcNAc testing is more expensive than blood biomarkers, it provides direct evidence of CNS target engagement that blood-based markers cannot replicate. For OGA inhibitor trials, the cost is justified by its role in dose-selection and proof-of-mechanism.

Measurement Methods

Current Standard: LC-MS/MS

The gold standard for CSF O-GlcNAc quantification uses liquid chromatography-tandem mass spectrometry (LC-MS/MS):

Alternative Methods

| Method | Advantages | Limitations |
|--------|------------|-------------|
| Lectin blotting | Low cost, fast | Semi-quantitative, lower sensitivity |
| Chemical labeling + ELISA | High throughput | Requires antibody to O-GlcNAc |
| Capillary electrophoresis | Low sample volume | Less widely available |

Biomarker Kinetics

Timeline of CSF O-GlcNAc Changes After OGA Inhibitor Dosing:

Day 0 Day 1 Day 3 Day 7 Day 14 Day 28
| | | | | |
|-------+-------+--------+--------+--------+------> O-GlcNAc Level
| | | | | |
Dose Peak Plateau Sustained Sustained Steady State
Start Effect Effect Effect Effect (if chronic)

• Onset: CSF O-GlcNAc increases detectable within 4-8 hours of first dose
• Peak: Maximum elevation typically achieved within 3-7 days of dosing
• Plateau: Steady-state levels maintained with continued dosing
• Recovery: Return to baseline within 1-2 weeks after drug discontinuation

Correlation with Disease Biomarkers

Relationship to Tau Biomarkers

Clinical trials are exploring correlations between CSF O-GlcNAc elevation and downstream tau biomarkers:

| Tau Biomarker | Expected Correlation | Evidence Status |
|---------------|---------------------|-----------------|
| p-tau181 | Inverse (↑O-GlcNAc → ↓p-tau) | Modest reductions observed in MAGNOLIA |
| p-tau217 | Inverse | Pending LOTUS/PROSPER data |
| Total tau | No direct correlation | Not expected to change |
| Tau PET | Inverse (planned) | Correlative studies ongoing |

Relationship to Neurodegeneration Markers

| Marker | Expected Direction | Rationale |
|--------|-------------------|-----------|
| NfL (neurofilament light) | No change expected | Marker of neuronal injury, not directly modulated by OGA |
| GFAP | No change expected | Astrocyte marker, not O-GlcNAc dependent |

Integration with OGA Inhibitor Development

Clinical Development Decision Matrix

Target Engagement Thresholds

Based on clinical trial data, the following CSF O-GlcNAc elevations are associated with target engagement:

| Expected Increase | Classification | Clinical Interpretation |
|-------------------|----------------|------------------------|
| <20% from baseline | Suboptimal | May not achieve sufficient CNS target engagement |
| 20-50% | Moderate | Target engagement achieved, proceed |
| 50-100% | Robust | Strong target engagement |
| >100% | High | Maximum practical engagement (consider dose reduction if side effects) |

Challenges and Limitations

Current Limitations

Future Directions

• Blood-based O-GlcNAc: PBMC (peripheral blood mononuclear cell) O-GlcNAc as less invasive alternative under investigation
• PET ligands: O-GlcNAc-specific PET tracers in development
• Combination panels: CSF O-GlcNAc + p-tau + NfL as integrated biomarker panel

Cross-Links

• [OGA Inhibitor Landscape](/therapeutics/oga-inhibitor-landscape) — Hub page for all OGA inhibitor programs
• [LY3372689 MAGNOLIA Trial](/clinical-trials/ly3372689-magnolia-phase2-ad) — Phase 2 AD trial with biomarker endpoints
• [FNP-223 PROSPER Trial](/clinical-trials/fnp223-prosper-phase2-psp) — Phase 2 PSP trial with CSF biomarker
• [LY3372689 LOTUS Trial](/clinical-trials/ly3372689-lotus-phase2-psp) — Phase 2 PSP trial
• [O-GlcNAcylation Pathway](/mechanisms/protein-o-glcna-cylation-pathway) — Biochemical mechanism
• [MGEA5 Gene](/genes/mgea5) — OGA encoding gene
• [OGT Gene](/genes/ogt) — O-GlcNAc transferase gene
• [Dr. Susan M. Catalano](/researchers/susan-catalano) — CSF O-GlcNAc biomarker development

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CSF O-GlcNAc — Target Engagement Biomarker for OGA Inhibitors discovered through SciDEX knowledge graph analysis: